Tongjitang Chinese Medicines Company Announces Share Repurchase Program

SHENZHEN, China--(BUSINESS WIRE)--Tongjitang Chinese Medicines Company (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced that the company has been approved, but not obligated, by its board of directors to purchase up to $20 million of its American Depositary Shares ("ADS"), subject to shareholder approval.